Literature DB >> 27335400

Rescue of the Functional Alterations of Motor Cortical Circuits in Arginase Deficiency by Neonatal Gene Therapy.

Gloria Cantero1, Xiao-Bo Liu2, Ronald F Mervis3, Maria T Lazaro4, Stephen D Cederbaum5, Peyman Golshani6, Gerald S Lipshutz7.   

Abstract

UNLABELLED: Arginase 1 deficiency is a urea cycle disorder associated with hyperargininemia, spastic diplegia, loss of ambulation, intellectual disability, and seizures. To gain insight on how loss of arginase expression affects the excitability and synaptic connectivity of the cortical neurons in the developing brain, we used anatomical, ultrastructural, and electrophysiological techniques to determine how single-copy and double-copy arginase deletion affects cortical circuits in mice. We find that the loss of arginase 1 expression results in decreased dendritic complexity, decreased excitatory and inhibitory synapse numbers, decreased intrinsic excitability, and altered synaptic transmission in layer 5 motor cortical neurons. Hepatic arginase 1 gene therapy using adeno-associated virus rescued nearly all these abnormalities when administered to neonatal homozygous knock-out animals. Therefore, gene therapeutic strategies can reverse physiological and anatomical markers of arginase 1 deficiency and therefore may be of therapeutic benefit for the neurological disabilities in this syndrome. SIGNIFICANCE STATEMENT: These studies are one of the few investigations to try to understand the underlying neurological dysfunction that occurs in urea cycle disorders and the only to examine arginase deficiency. We have demonstrated by multiple modalities that, in murine layer 5 cortical neurons, a gradation of abnormalities exists based on the functional copy number of arginase: intrinsic excitability is altered, there is decreased density in asymmetrical and perisomatic synapses, and analysis of the dendritic complexity is lowest in the homozygous knock-out. With neonatal administration of adeno-associated virus expressing arginase, there is near-total recovery of the abnormalities in neurons and cortical circuits, supporting the concept that neonatal gene therapy may prevent the functional abnormalities that occur in arginase deficiency.
Copyright © 2016 the authors 0270-6474/16/366680-11$15.00/0.

Entities:  

Keywords:  adeno-associated virus; arginase deficiency; electrophysiology; gene therapy; motor cortex; synapses

Mesh:

Substances:

Year:  2016        PMID: 27335400      PMCID: PMC4916246          DOI: 10.1523/JNEUROSCI.0897-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  28 in total

1.  Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia.

Authors:  Joshua L Deignan; Peter P De Deyn; Stephen D Cederbaum; Arno Fuchshuber; Bernhard Roth; Wieland Gsell; Bart Marescau
Journal:  Mol Genet Metab       Date:  2010-01-29       Impact factor: 4.797

2.  Detection of spontaneous synaptic events with an optimally scaled template.

Authors:  J D Clements; J M Bekkers
Journal:  Biophys J       Date:  1997-07       Impact factor: 4.033

3.  Long-term potentiation is associated with changes in synaptic ultrastructure in the rat neocortex.

Authors:  S Connor; P T J Williams; B Armstrong; T L Petit; T L Ivanco; A C W Weeks
Journal:  Synapse       Date:  2006-05       Impact factor: 2.562

4.  RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy.

Authors:  Chuhong Hu; Ronald W Busuttil; Gerald S Lipshutz
Journal:  J Gene Med       Date:  2010-09       Impact factor: 4.565

Review 5.  The human arginases and arginase deficiency.

Authors:  R Iyer; C P Jenkinson; J G Vockley; R M Kern; W W Grody; S Cederbaum
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

Review 6.  Ammonia: key factor in the pathogenesis of hepatic encephalopathy.

Authors:  R F Butterworth; J F Giguère; J Michaud; J Lavoie; G P Layrargues
Journal:  Neurochem Pathol       Date:  1987 Feb-Apr

7.  Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.

Authors:  Chia-Ling Gau; Robin A Rosenblatt; Vincenzo Cerullo; Fides D Lay; Adrienne C Dow; Justin Livesay; Nicola Brunetti-Pierri; Brendan Lee; Stephen D Cederbaum; Wayne W Grody; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

8.  The urea cycle disorders.

Authors:  Guy Helman; Ileana Pacheco-Colón; Andrea L Gropman
Journal:  Semin Neurol       Date:  2014-09-05       Impact factor: 3.420

9.  Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice.

Authors:  Chuhong Hu; Jennifer Kasten; Hana Park; Ragini Bhargava; Denise S Tai; Wayne W Grody; Quynh G Nguyen; Stephen D Hauschka; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2014-06-03       Impact factor: 11.454

10.  Taurine in hippocampus: localization and postsynaptic action.

Authors:  K H Taber; C T Lin; J W Liu; R H Thalmann; J Y Wu
Journal:  Brain Res       Date:  1986-10-29       Impact factor: 3.252

View more
  6 in total

1.  Hepatic arginase deficiency fosters dysmyelination during postnatal CNS development.

Authors:  Xiao-Bo Liu; Jillian R Haney; Gloria Cantero; Jenna R Lambert; Marcos Otero-Garcia; Brian Truong; Andrea Gropman; Inma Cobos; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  JCI Insight       Date:  2019-09-05

Review 2.  CPS1: Looking at an ancient enzyme in a modern light.

Authors:  Matthew Nitzahn; Gerald S Lipshutz
Journal:  Mol Genet Metab       Date:  2020-10-10       Impact factor: 4.797

Review 3.  The Arginase Pathway in Neonatal Brain Hypoxia-Ischemia.

Authors:  Jana Krystofova; Praneeti Pathipati; Jeffrey Russ; Ann Sheldon; Donna Ferriero
Journal:  Dev Neurosci       Date:  2019-04-17       Impact factor: 2.984

4.  Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency.

Authors:  Suhail Khoja; Xiao-Bo Liu; Brian Truong; Matthew Nitzahn; Jenna Lambert; Adam Eliav; Eram Nasser; Emma Randolph; Kristine E Burke; Rebecca White; Xuling Zhu; Paolo G V Martini; Itzhak Nissim; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-27       Impact factor: 10.183

5.  Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.

Authors:  Brian Truong; Gabriella Allegri; Xiao-Bo Liu; Kristine E Burke; Xuling Zhu; Stephen D Cederbaum; Johannes Häberle; Paolo G V Martini; Gerald S Lipshutz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

6.  Activation of TRPV1 Contributes to Recurrent Febrile Seizures via Inhibiting the Microglial M2 Phenotype in the Immature Brain.

Authors:  Weilin Kong; Xin Wang; Xingliang Yang; Wenxian Huang; Song Han; Jun Yin; Wanhong Liu; Xiaohua He; Biwen Peng
Journal:  Front Cell Neurosci       Date:  2019-10-11       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.